DexCom (NASDAQ:DXCM) Insider Kevin Sayer Sells 26,759 Shares

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,759 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the transaction, the insider directly owned 382,482 shares of the company’s stock, valued at $27,538,704. This represents a 6.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Trading Down 0.1%

DexCom stock opened at $72.01 on Wednesday. The company has a 50 day moving average price of $63.87 and a 200 day moving average price of $66.18. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The firm has a market capitalization of $27.79 billion, a price-to-earnings ratio of 30.77, a P/E/G ratio of 1.19 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter last year, the business posted $0.32 EPS. The company’s revenue was up 15.0% on a year-over-year basis. Research analysts forecast that DexCom, Inc. will post 2.57 EPS for the current year.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of DexCom by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock valued at $3,327,897,000 after buying an additional 1,133,638 shares during the period. Geode Capital Management LLC boosted its stake in shares of DexCom by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock valued at $727,842,000 after buying an additional 42,411 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of DexCom by 6.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock valued at $530,897,000 after purchasing an additional 516,526 shares during the last quarter. Norges Bank acquired a new stake in shares of DexCom in the 4th quarter valued at $483,356,000. Finally, Invesco Ltd. lifted its stake in shares of DexCom by 14.8% in the 4th quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after purchasing an additional 686,228 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Raymond James Financial set a $81.00 price objective on shares of DexCom in a research note on Friday, May 1st. Truist Financial reaffirmed a “buy” rating and issued a $80.00 price objective (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Piper Sandler reissued an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Canaccord Genuity Group set a $82.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Monday, May 18th. Finally, BTIG Research reissued a “buy” rating and set a $85.00 target price on shares of DexCom in a research note on Monday, March 9th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $82.21.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.